These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16504599)

  • 1. Diabetes: assessing the pipeline.
    Lebovitz H
    Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.
    Lebovitz HE
    Endocr Pract; 2006; 12 Suppl 1():142-7. PubMed ID: 16627399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for type 2 diabetes mellitus: what is their place in therapy?
    Krentz AJ; Patel MB; Bailey CJ
    Drugs; 2008; 68(15):2131-62. PubMed ID: 18840004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
    Charbonnel B
    Lancet; 2009 Jul; 374(9684):96-8. PubMed ID: 19515412
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tesaglitazar: a promising approach in type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N
    South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
    Kalliora C; Drosatos K
    J Cardiovasc Pharmacol; 2020 Nov; 76(5):514-526. PubMed ID: 33165133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.